Cell Therapy Clinical Trials Looks Promising With More Than 700 Therapies In Clinical Pipeline

"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights:

o Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026
o Cell Therapy Clinical Trial Insight by Indication, Company & Country
o Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
o Globally Marketed Cell Therapies: 25 Cell Therapies
o Maximum Number of Marketed Cell Therapies In USA: 15 Therapies
o Price & Product Insight By Region/Country
o Regional Analysis of the Cell Therapy Market

Download Report:

https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php

Contact: neeraj@kuickresearch or +91-9810410366 for report details.

Table of Contents

1. Overview of Cell Therapy
1.1 Introduction to Cell Therapy
1.2 History & Evolution of Cell Therapy

2. Types of Cell Therapy
2.1 Allogeneic Cell Therapy
2.2 Autologous Cell Therapy
2.3 Human Embryonic Stem Cell Therapy
2.4 Neural Stem Cell Therapy
2.5 Mesenchymal Stem Cell Therapy
2.6 Hematopoietic Stem Cell Transplantation

3. Mechanism of Therapeutic Action in Cell Therapy

4. Manufacturing of Cell Therapies
4.1 Models for Manufacturing Cell Therapies
4.2 Facilities for Good Manufacturing Practice

5. Advantages of Cell Therapy Over Conventional Therapy
5.1 Anti-Aging with Cell Therapy
5.2 Addressing Other Diseases with Cell Therapy

6. Personalized Cell Therapy
6.1 Overview of Personalized Cell Therapy
6.2 Personalized Cell Therapy Using Epigenetic Tools
6.3 Personalized Cell Therapy through Mesenchymal Stem Cells
6.4 Treatment of Parkinson's Disease through IPSCs
6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

7. Cell Therapy Application by Therapeutic Areas
7.1 Cardiovascular Disease
7.2 Neurological Disorders
7.3 Inflammatory Diseases
7.4 Diabetes
7.5 Cancer

8. Global Cell Therapy Market Outlook
8.1 Current Market Scenario
8.2 Cell Therapy Market by Cell Source
8.2.1 Induced Pluripotent Stem Cell (IPSCs)
8.2.2 Bone Marrow
8.2.3 Umbilical Cord Blood Derived Cells
8.3 Global Cell Therapy Clinical Pipeline (Company,Indication, Region) Overview

9. US - Cell Therapy Dosage & Cost Analysis
9.1 Allocord
9.2 Laviv
9.3 Maci
9.4 Clevecord
9.5 Hemacord
9.6 Ducord
9.7 Provenge
9.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
9.10 HPC, Cord Blood (Bloodworks)
9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
9.12 Gintuit
9.13 Kymriah*
9.14 Yescarta*
9.15 Carticel

10. South Korea - Cell Therapy Dosage & Cost Analysis
10.1 Cartistem
10.2 Chondron
10.3 KeraHeal
10.4 Cellgram
10.5 Cure Skin Injection

11. Australia, Europe & Japan - Cell Therapy Dosage & Cost Analysis
11.1 Holoclar (Europe)
11.2 Yescarta (EU)
11.3 Kymriah (EU)
11.4 Temcell HS (Japan)
11.5 Chondrocytes-T-Ortho-ACI (Australia)

12. Cell Therapy Market Trends: Geographically
12.1 US
12.2 South Korea
12.3 Europe
12.4 Japan
12.5 China
12.6 Rest of the World
12.6.1 Africa
12.6.2 Middle East
12.6.3 South America

13. Advancements in Cell Therapy
13.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia
13.2 Advances in Cytomegalovirus Infection Prevention & Treatment
13.3 Stem Cell Therapy for the Treatment of Parkinson's Disease
13.4 Stem Cell Therapy for the Treatment of Alzheimer's Disease
13.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy
13.6 Role of Stem Cell Therapy in Treating Infertility
13.7 Stem Cells for Eye Diseases
13.8 Cell Therapy for Stroke and Angina Pectoris
13.9 Stem Cell Therapy in Improving Wrinkles & Acne Scars

14. Treg Cells - The Next Edge of Cell Therapy
14.1 Introduction to Treg Cell
14.2 Isolation & Expansion of Treg Cell
14.3 Mechanism of Action
14.4 Clinical Trials of Treg Cell Therapy
14.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD
14.4.2 Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg cells to Prevent Solid Organ Transplant Rejection
14.5 Treg Cell Therapy for the Treatmet of Autoinflammatory & Autoimmune Diseases
14.5.1 Inflammatory Bowel Disease
14.5.2 Systemic Lupus Erythematosus
14.5.3 Autoimmune Hepatitis
14.5.4 Pemphigus Vulgaris
14.5.5 Allergy and Asthma
14.6 Future Prospects of Treg Cell Therapy

15. Global Cell Therapy Market Dynamics
15.1 Market Drivers
15.2 Commercial Challenges

16. Global Cell Therapy Market Future Prospects


17. Marketed Cell Therapies Clinical Insight by Company & Indication
17.1 Tisagenlecleucel (Kymriah)
17.2 Axicabtagene Ciloleucel (Yescarta)
17.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)
17.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
17.5 Tonogenchoncel-L (INVOSSA-K inj)
17.6 Mesenchymal Stem Cell Therapies (Stempeucel)
17.7 Remestemcel-L (Prochymal & TEMCELL HS Inj.)
17.8 Sipuleucel-T (Provenge)
17.9 Autologous Mesenchymal Stem Cell Therapy - Pharmicell
17.10 Autologous Cultured Chondrocytes (MACI)
17.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
17.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
17.13 Nalotimagene Carmaleucel (Zalmoxis)
17.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)
17.15 Autologous Chondrocyte Implant - TETEC
17.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)
17.17 Human Skin Replacement (CellSpray)
17.18 Leukocyte Cell Therapy (CureXcell)
17.19 Autologous Cultured Chondrocyte Implant (Carticel)
17.20 Azficel-T (Laviv)
17.21 Autologous Cultured Chondrocytes (CHONDRON)
17.22 Autologous Chondrocytes (BioCart)
17.23 Amniotic Cell Therapy (NuCel)
17.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
17.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)

18. Global Cell Therapy Clinical Pipeline by Company, Indication & Phase
18.1 Research
18.2 Preclinical
18.3 Clinical
18.4 Phase-0
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered

19. Competitive Landscape
19.1 Athersys Inc.
19.2 Baxter Healthcare Corporation
19.3 Bone Therapeutics
19.4 Celgene Corporation
19.5 Cell Medica
19.6 Cellerant Therapeutics
19.7 FibrocellScinence
19.8 Genzyme Corporation
19.9 Green Cross Cell
19.10 Histogenics Corporation
19.11 Intrexon Corporation
19.12 Intercytex
19.13 ISTO Biologics
19.14 Macrocure
19.15 Mesoblast
19.16 Molmed
19.17 Nuo Therapeutics Inc
19.18 OmniCyte
19.19 Opexa Therapeutics
19.20 Organogenesis
19.21 Pharmicell
19.22 TCA Cellular Therapy
19.23 Stem Cell Inc.
19.24 Teva Pharmaceuticals
19.25 Tigenix
19.26 Vericel Corporation

Kuick Research
Delhi,India,Tel; +91-11-47067990

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.